Publisher Full Text
Plasma total homocysteine levels and methylenetetrahydrofolate reductase gene polymorphism in patients with type 2 diabetes mellitus.Pathophysiol Haemost Thromb. 2008; 36(5):275-81.PH
Abstract
BACKGROUND
Thrombotic episodes account for approximately 80% of deaths in type 2 diabetic patients. Hyperhomocysteinaemia is a well recognized independent risk factor for atherosclerosis and thromboembolism. Increased homocysteine levels may occur due to a number of factors including inherited gene polymorphism of methylenetetrahydrofolate reductase (MTHFR) C677T. Here, we evaluate plas- ma total homocysteine (tHcy) levels and frequency of the MTHFR C677T gene polymorphism in asymptomatic healthy volunteers and type 2 diabetic patients with hypertension but without nephropathy. We have also investigated the relationship between tHcy levels and the presence of MTHFR C677T gene polymorphism.
METHODS
Plasma tHcy levels and MTHFR C677T genotype were investigated in a total of 53 subjects. These included asymptomatic healthy volunteers (n = 16), patients with type 2 diabetes (n = 7), subjects with hypertension (n = 12) and patients with both type 2 diabetes and hypertension (n = 18). Renal function, serum lipids and other metabolites were also assessed.
RESULTS
There was no significant difference in tHcy levels between the groups studied. The frequency of MTHFR C677T gene polymorphism observed was similar to that obtained for the general Brazilian population. In patients with type 2 diabetes and hypertension but without impaired renal function, we observed no meaningful correlation between increased tHcy levels and the presence of MTHFR C677T gene polymorphism.
CONCLUSIONS
Type 2 diabetics who are homozygous or heterozygous for the MTHFR C677T gene polymorphism showed normal tHcy levels. Our results further suggest that diabetes without an associated adverse risk profile is not an independent correlate of increased tHcy levels.
Links
MeSH
Pub Type(s)
Journal Article
Research Support, Non-U.S. Gov't
Language
eng
PubMed ID
19996639
Citation
Soares, Anna L., et al. "Plasma Total Homocysteine Levels and Methylenetetrahydrofolate Reductase Gene Polymorphism in Patients With Type 2 Diabetes Mellitus." Pathophysiology of Haemostasis and Thrombosis, vol. 36, no. 5, 2008, pp. 275-81.
Soares AL, Fernandes AP, Cardoso JE, et al. Plasma total homocysteine levels and methylenetetrahydrofolate reductase gene polymorphism in patients with type 2 diabetes mellitus. Pathophysiol Haemost Thromb. 2008;36(5):275-81.
Soares, A. L., Fernandes, A. P., Cardoso, J. E., Sousa, M. O., Lasmar, M. C., Novelli, B. A., Lages, G. F., Dusse, L. M., Vieira, L. M., Lwaleed, B. A., & Carvalho, M. G. (2008). Plasma total homocysteine levels and methylenetetrahydrofolate reductase gene polymorphism in patients with type 2 diabetes mellitus. Pathophysiology of Haemostasis and Thrombosis, 36(5), 275-81. https://doi.org/10.1159/000252825
Soares AL, et al. Plasma Total Homocysteine Levels and Methylenetetrahydrofolate Reductase Gene Polymorphism in Patients With Type 2 Diabetes Mellitus. Pathophysiol Haemost Thromb. 2008;36(5):275-81. PubMed PMID: 19996639.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Plasma total homocysteine levels and methylenetetrahydrofolate reductase gene polymorphism in patients with type 2 diabetes mellitus.
AU - Soares,Anna L,
AU - Fernandes,Ana P,
AU - Cardoso,Jarbas E,
AU - Sousa,Marinez O,
AU - Lasmar,Marcelo C,
AU - Novelli,Bethânia A,
AU - Lages,Geralda F,
AU - Dusse,Luci M,
AU - Vieira,Lauro M,
AU - Lwaleed,Bashir A,
AU - Carvalho,Maria G,
Y1 - 2009/12/09/
PY - 2009/04/22/received
PY - 2009/07/06/accepted
PY - 2009/12/10/entrez
PY - 2008/1/1/pubmed
PY - 2010/2/24/medline
SP - 275
EP - 81
JF - Pathophysiology of haemostasis and thrombosis
JO - Pathophysiol Haemost Thromb
VL - 36
IS - 5
N2 - BACKGROUND: Thrombotic episodes account for approximately 80% of deaths in type 2 diabetic patients. Hyperhomocysteinaemia is a well recognized independent risk factor for atherosclerosis and thromboembolism. Increased homocysteine levels may occur due to a number of factors including inherited gene polymorphism of methylenetetrahydrofolate reductase (MTHFR) C677T. Here, we evaluate plas- ma total homocysteine (tHcy) levels and frequency of the MTHFR C677T gene polymorphism in asymptomatic healthy volunteers and type 2 diabetic patients with hypertension but without nephropathy. We have also investigated the relationship between tHcy levels and the presence of MTHFR C677T gene polymorphism. METHODS: Plasma tHcy levels and MTHFR C677T genotype were investigated in a total of 53 subjects. These included asymptomatic healthy volunteers (n = 16), patients with type 2 diabetes (n = 7), subjects with hypertension (n = 12) and patients with both type 2 diabetes and hypertension (n = 18). Renal function, serum lipids and other metabolites were also assessed. RESULTS: There was no significant difference in tHcy levels between the groups studied. The frequency of MTHFR C677T gene polymorphism observed was similar to that obtained for the general Brazilian population. In patients with type 2 diabetes and hypertension but without impaired renal function, we observed no meaningful correlation between increased tHcy levels and the presence of MTHFR C677T gene polymorphism. CONCLUSIONS: Type 2 diabetics who are homozygous or heterozygous for the MTHFR C677T gene polymorphism showed normal tHcy levels. Our results further suggest that diabetes without an associated adverse risk profile is not an independent correlate of increased tHcy levels.
SN - 1424-8840
UR - https://www.unboundmedicine.com/medline/citation/19996639/Plasma_total_homocysteine_levels_and_methylenetetrahydrofolate_reductase_gene_polymorphism_in_patients_with_type_2_diabetes_mellitus_
L2 - https://www.karger.com?DOI=10.1159/000252825
DB - PRIME
DP - Unbound Medicine
ER -
